U.S. Biosimilar Market Size Worth USD 30.2 by 2033 | CAGR: 18.5%

United States Biosimilar Market Overview

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Growth Rate: 18.5% (2025-2033)

Market Size in 2024: USD 6.5 Billion

Market Forecast in 2033: USD 30.2 Billion

The United States biosimilar market is experiencing significant growth, driven by several key factors. One primary driver is the increasing number of biologic drugs losing patent protection, which opens the market to biosimilar competition. Between 2020 and 2025, 17 blockbuster biologics with annual peak sales totaling $60 billion are expected to lose exclusivity, providing substantial opportunities for biosimilar manufacturers. This influx of biosimilars enhances patient access to essential therapies by offering more affordable alternatives to high-cost biologics. Additionally, the U.S. Food and Drug Administration (FDA) has been actively approving biosimilars, with 60 biosimilars approved as of October 2024, reflecting a supportive regulatory environment that encourages market entry and competition.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/united-states-biosimilar-market/requestsample

United States Biosimilar Industry Trends and Drivers:

Another significant factor propelling the U.S. biosimilar market is the strategic decisions by major pharmacy benefit managers (PBMs) to favor biosimilars over original biologics in their formularies. For instance, companies like Cigna and UnitedHealth Group have announced plans to remove AbbVie’s Humira from some of their preferred drug reimbursement lists, opting instead to recommend lower-cost biosimilar versions. These moves by PBMs, which manage a substantial portion of the U.S. pharmaceutical market, are expected to accelerate the adoption of biosimilars, leading to increased market penetration and significant cost savings for patients and the healthcare system. Furthermore, the rising prevalence of chronic diseases such as cancer and diabetes necessitates more cost-effective treatment options, further driving the demand for biosimilars. Besides this, the U.S. biosimilar market growth is rapid  due to the rising demand for cost-effective biologic alternatives, an aging population, and an increasing prevalence of chronic diseases. Biologics play a critical role in treating conditions such as cancer, autoimmune disorders, and diabetes, but their high costs often limit patient access. Biosimilars, which offer similar efficacy and safety profiles at lower prices, are addressing this issue, leading to increased adoption. The cost savings associated with biosimilars are substantial, with estimates suggesting that they could save the U.S. healthcare system billions of dollars annually. As healthcare spending continues to rise, payers, including Medicare, Medicaid, and private insurers, are pushing for greater biosimilar use to reduce financial burdens. Additionally, biosimilars are expected to improve healthcare equity by making advanced biologic treatments accessible to a larger patient population.

United States Biosimilar Industry Segmentation:

The report has segmented the market into the following categories:

Molecule Insights:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

Manufacturing Type Insights:

• In-house Manufacturing
• Contract Manufacturing

Indication Insights:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

Regional Insights:

• Northeast
• Midwest
• South
• West

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Ask Our Expert & Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=11073&flag=C

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: [email protected] 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145